NovoCure Limited

18.51
0.74 (4.16%)
At close: Apr 24, 2025, 3:59 PM
19.22
3.83%
After-hours: Apr 24, 2025, 07:36 PM EDT

Company Description

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China.

Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma.

The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer.

NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.

NovoCure Limited
NovoCure Limited logo
Country JE
IPO Date Oct 1, 2015
Industry Medical - Instruments & Supplies
Sector Healthcare
Employees 1,488
CEO William F. Doyle

Contact Details

Address:
No. 4 The Forum
Saint Helier,
JE
Website https://www.novocure.com

Stock Details

Ticker Symbol NVCR
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001645113
CUSIP Number G6674U108
ISIN Number JE00BYSS4X48
Employer ID 00-0000000
SIC Code 3841

Key Executives

Name Position
Barak Ben-Arye General Counsel
Dr. Nicolas Leupin M.B.A., M.D., Ph.D. Chief Medical Officer
William F. Doyle Executive Chairman

Latest SEC Filings

Date Type Title
Apr 23, 2025 SCHEDULE 13G/A [Amend] Filing
Apr 22, 2025 8-K Current Report
Apr 21, 2025 DEFA14A Filing
Apr 21, 2025 DEF 14A Filing
Apr 01, 2025 SCHEDULE 13G Filing
Mar 06, 2025 4 Filing
Mar 06, 2025 4 Filing
Mar 06, 2025 4 Filing
Mar 06, 2025 4 Filing
Mar 06, 2025 4 Filing